Investor Relations
9 August 2021(星期一)
2021 Interim Results Announcement
Dear Investors and Analysts,
9 August 2021 – Hua Medicine (2552.HK) ("Hua Medicine" or the "Company") cordially invites you or your representative to attend the online webinar in relation to its 2021 interim results on 19 August 2021 (Thursday) at 3:00 PM Hong Kong Time.
During the webinar, management will review the business and financial performance in the first half of 2021 and share with you their future plans.
Details of the webinar are as follows:
Date: | 19 August 2021 (Thursday) |
Time: |
Login starts: 2:45PM Hong Kong Time |
Duration: | 1 hour (including Q&A session) |
Meeting Language: | English |
Management: |
Mr. Li Chen, Chief Executive Officer and Chief Scientific Officer |
RSVP: |
Registration Link: |
Q&A Arrangement: |
If you would like to raise questions, please send your questions to huamedicine@icaasia.com from now till 19 August 2021 (Thursday). |
About Hua Medicine |
Hua Medicine is a leading, innovative biotechnology company in China focused on developing novel therapies for diseases with unmet medical needs. Founded by an experienced group of entrepreneurs and international investment firms, Hua Medicine advanced a first-in-class oral drug for the treatment of T2DM into NDA stage, and it has successfully completed two Phase III registration trials in China for dorzagliatin. The Company has initiated product life-cycle management studies of this novel diabetes therapy and advanced its use in personalized diabetes care. Hua Medicine is working closely with disease experts and regulatory agencies in China and across the world to advance diabetes care solutions for patients worldwide. |
滬ICP備14036654號(hào)-1
滬公網(wǎng)安備 31011502013809號(hào) Privacy Statement Terms of Use
